|
Study ID
|
ACCP002.2
|
|
Investigator
|
Donald B Fuller, MD, CyberKnife Centers at San Diego, CA
George Mardirossian, PhD, CyberKnife Centers of San Diego, CA
|
|
Title
|
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
|
|
Conditions
|
Prostate Cancer
Prostatic Cancer
Prostatic Neoplasms
Prostate Neoplasms
Cancer of the Prostate
|
|
Interventions
|
Radiation: CyberKnife Stereotactic Radiosurgery
|
|
Phase
|
Phase 2
|
|
Purpose
|
The purpose of this study is to investigate the effects of CyberKnife radiosurgery in
patients with early stage organ-confined prostate cancer and to evaluate the effects of this
treatment on the quality of life over time.
|
|
Eligibility
|
Ages Eligible: 18 Years
Genders Eligible:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:- Patient must be at least 18 years of age
- Histologically proven prostate adenocarcinoma
- Biopsy within 1 year of date of registration
- Clinical Stage T1b-T2b, N0, M0
- Patients belonging to one of the following risk categories:
- Low Risk: CS T1b-T2a, Gleason Score 2-6, PSA < or = 10 ng/ml
- Intermediate Risk: CS T2b, Gleason Score 2-6, PSA < or = 10 ng/ml or CS T1b-T2b,
Gleason Score 2-6, PSA < or = 20 ng/ml or CS T1b-T2b, Gleason Score 7 and PSA < or =
10 ng/ml
- ECOG performance status 0-1
Exclusion Criteria:- Clinical Stage T2c or greater
- Prior prostatectomy or cryotherapy of the prostate
- Prior radiotherapy fo the prostate or lower pelvis
- Implanted hardware or other material that would prohibit appropriate treatment
planning or delivery
- History of an invasive malignancy other than basal or squamous skin cancers in the
last 5 years
- Hormone ablation for two months prior to enrollment or during treatment
|
|
Study Location
|
N/A
|
|
Contact
|
N/A
|
Information obtained from ClinicalTrials.gov, on
6/18/2013. For additional information about
this and other clinical trials,
visit http://clinicaltrials.gov.
Please refer to this study by its ClinicalTrials.gov identifier:
NCT00643617
|
|